AVEO Oncology (NASDAQ:AVEO) today reported its third quarter 2014 financial results and provided an overview of its progress toward achieving its strategic plan.
“At AVEO, we continue to execute on all aspects of our strategic plan. We are focused on the progression of AV-380 in cancer cachexia toward an IND application filing next year, while remaining opportunistic to leveraging partner resources with the rest of our pipeline,” said Tuan Ha-Ngoc, president and chief executive officer of AVEO. “
Help employers find you! Check out all the jobs and post your resume.
“At AVEO, we continue to execute on all aspects of our strategic plan. We are focused on the progression of AV-380 in cancer cachexia toward an IND application filing next year, while remaining opportunistic to leveraging partner resources with the rest of our pipeline,” said Tuan Ha-Ngoc, president and chief executive officer of AVEO. “
Help employers find you! Check out all the jobs and post your resume.
